important negative trials

This trial tested the safety and efficacy of levosimendan in improving supine slow vital capacity after 12 weeks of treatment in 496 people with amyotrophic lateral sclerosis.

The objective of this study was to determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19.

In this study the authors conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 d of respiratory symptom onset (NCT04348656).

In this study the authors aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support.